Thermo Fisher Scientific IL-28A Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

0.1 µg/mL

-

Immunocytochemistry (ICC/IF)

5-15 µg/mL

-

ELISA (ELISA)

Assay-Dependent

-

Neutralization (Neu)

0.3-1.5 µg/mL

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Goat / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Mouse myeloma cell line NS0-derived recombinant human IL-28A/IFN-lambda 2 Val26-Val200 if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:IL-28A,uniProtId:Q8IZJ0-1,ncbiNodeId:9606,antigenRange:26-200,antigenLength:200,antigenImageFileName:PA5-47163_IL-28A_Q8IZJ0-1_Goat.svg,antigenImageFileNamePDP:PA5-47163_IL-28A_Q8IZJ0-1_Goat_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Concentration

0.2 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS with 5% trehalose

Contains

No Preservative

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2606773

Product Specific Information

In direct ELISAs and Western blots, approximately 60% cross-reactivity with human IL-28B/IFN- lambda 3 is observed. In direct ELISAs, approximately 30% cross-reactivity with recombinant human IL-29 and less than 5% cross-reactivity with recombinant mouse IL-28 is observed.

Reconstitute at 0.2 mg/mL in sterile PBS.

Endoxin level is <0.10 EU per 1 µg of the antibody by the LAL method.

Target Information

IL-28A belongs to the IFN lambda family, a novel family of cytokines within the IL-10 superfamily. The three members of this family are IL-29 (IFN lambda 1), IL-28A (IFN lambda 2), and IL-28B (IFN lambda 3), and are also known as the type III Interferons.The IFN lambdas signal through a heterodimeric receptor of which one subunit, IL-10R2, is shared with other members of the superfamily. The second subunit, IFN lambda R1 or IL-28R alpha, is unique to the IFN lambdas. Signaling occurs through the Jak/STAT pathway in a similar manner as the type I IFN (IFN alpha/beta) and activates many of the same genes despite low sequence homology between the cytokines and receptors in the two families. Both IFN families display antiviral activity through the induction of antiviral protein production in target cells and the upregulation of MHC class I expression. These proteins also exhibit antiproliferative and antitumor effects, making them a possible alternative to IFN alpha cancer therapies. Unlike the type I IFN, which are able to stimulate most cells, response to IFN lambda stimulation appears to be limited to dendritic and some tumor cells due to the limited expression of IFN lambda R1. Another notable difference is the ability of the IFN lambda stimulation to drive dendritic cells towards the production of CD4+CD25+FoxP3+ regulatory T cells, suggesting a possible immunoregulatory role

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.